Drug Profile
Linagliptin/metformin - Boehringer Ingelheim/Eli Lilly and Company
Alternative Names: BI 10773/linagliptin FDC (high dose) - Boehringer Ingelheim; Jentadueto; Jentadueto XR; JentaDuo; linagliptin and metformin hydrochloride extended-release; Linagliptin/metformin FDC; Metformin/linagliptin; Trajenta DuoLatest Information Update: 14 Feb 2019
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Eli Lilly and Company
- Class Alkynes; Antihyperglycaemics; Biguanides; Insulin sensitisers; Piperidines; Purines; Quinazolines; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 14 Feb 2019 Chemical structure information added
- 15 Aug 2018 Depomed is now called Assertio Therapeutics
- 15 Dec 2016 Committee for Medicinal Products for Human Use (CHMP) of EMA adopts a positive opinion recommending approval of linagliptin/metformin for extension to an existing indication of Type-2 diabetes mellitus